Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2019 USD ($) installment	Dec. 31, 2021 USD ($)
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	$ 97,231	$ 104,031	$ 194,760	$ 192,876
Collaborative arrangements revenue
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	97,231	103,386	194,760	192,051
Sale of active pharmaceutical ingredient
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		645		825
AstraZeneca
Collaboration, License, Promotion and Other Commercial Agreements
Milestone payment to be received by company upon milestone achievement			90,000
Collaborative arrangement, significant financing component, transaction price	2,600		$ 2,600
Amount of non-contingent arrangement consideration					$ 35,000
Non-contingent consideration installments | installment					3
Percentage of tiered royalties			20.00%
Collaborative arrangement, non-contingent installment payments receivable	25,000		$ 25,000
Collaborative arrangement, non-contingent receivable, current	10,000		10,000
Collaborative arrangement, non-contingent receivable, non-current	14,300		14,300			$ 24,000
AstraZeneca | Collaborative arrangement, collaboration and license agreements
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	$ 148	200	340	410
AstraZeneca | Royalty
Collaboration, License, Promotion and Other Commercial Agreements
Revenue			$ 300	200
AstraZeneca | Sale of active pharmaceutical ingredient
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		$ 576		$ 597